



DOCKET NO.: CELL-0276/PA562.DIV

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Richard S. Dondero, et al.

Application No.: 10/684,774

Filing Date: October 14, 2003

For: INTERLEUKIN-1 MUTEINS USEFUL AS VACCINE

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: November 19, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
 - ☒ Copies of references 1-37 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/729,509, filed December 14, 2000.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: *November 19, 2003*



Jane E. Inglese
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



| | | | |
|---|----|--|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0276/PA562.div | Application No. 10/684,774 |
| | | Applicant Richard S. Dondero, et al. | |
| | | Filing Date October 14, 2003 | Group Not Yet Assigned |
| | | Confirmation No. Not Yet Assigned | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 1 | Boraschi and Tagliabue, "Interleukin-1 and Interleukin-1 Fragments as Vaccine Adjuvants", <i>Methods</i> , 1999 , 19, 108-113 | |
| | 2 | Carter, D.B., et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," <i>Nature</i> , April 1990 , 344, 633-638 | |
| | 3 | Clore, G.M., "High-resolution three-dimensional structure of interleukin 1 β in solution by three- and four-dimensional nuclear magnetic resonance spectroscopy," <i>Biochemistry</i> , 1991 , 30(9), 2315-2323 | |
| | 4 | DeChiara, T.M., et al., "Structure-function analysis of murine interleukin 1: biologically active polypeptides are at least 127 amino acids long and are derived from the carboxyl terminus of a 270-amino acid precursor," <i>Proc. Natl. Acad. Sci.</i> , November 1986 , 83, 8303-8307 | |
| | 5 | Dower, S.K., et al., "Detection and characterization of high affinity plasma membrane receptors for human interleukin 1," <i>J. Exp. Med.</i> , 1985 , 162, 501-515 | |
| | 6 | Dripps, D.J., et al., "Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction," <i>J. Biol. Chem.</i> , June 5, 1991 , 266(16), 10331-10336 | |
| | 7 | Driscoll, P.C., et al., "Complete resonance assignment for the polypeptide backbone of interleukin 1 β using three-dimensional heteronuclear NMR spectroscopy," <i>Biochemistry</i> , 1990 , 29(14), 3542-3556 | |
| | 8 | Finzel, B.C., et al., "Crystal structure of recombinant human interleukin-1 β at 2.0 Å resolution," <i>J. Mol. Biol.</i> , 1989 , 209, 779-791 | |
| | 9 | Graves, B.J., et al., "Structure of 1 α at 2.7 Å resolution," <i>Biochemistry</i> , 1990 , 29, 2679-2684 | |
| | 10 | Gronenborn, et al., "Site directed mutants of human interleukin-1 α : a H-NMR and receptor binding study," <i>Federation of European Biochemical Societies</i> , April 1998 , 231(1), 135-138 | |
| EXAMINER | | DATE CONSIDERED | |



| | | | |
|---|----|---|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0276/PA562.div | Application No. 10/684,774 |
| | | Applicant Richard S. Dondero, et al. | |
| | | Filing Date October 14, 2003 | Group Not Yet Assigned |
| | | Confirmation No. Not Yet Assigned | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 11 | Hannum, C.H., et al., "Interleukin-1 receptor antagonist activity of human interleukin-1 inhibitor," <i>Nature</i> , January 1990, 343, 336-340 | |
| | 12 | Huang, J.J., et al., "Muteins of human interleukin-1 that show enhanced bioactivities," <i>FEBS Letters</i> , November 1987, 223(2), 294-298 | |
| | 13 | Jobling, S.A., et al., "Biological activity and receptor binding of human prointerleukin-1 β and subpeptides," <i>J. Biol. Chem.</i> , November 5, 1988, 263, 16372-16378 | |
| | 14 | Ju, G.E., et al., "Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis," <i>Proc. Natl. Acad. Sci. USA</i> , April 1991, 88, 2658-2662 | |
| | 15 | Kramer, D.R., et al., "Cytokine mediated effects in mucosa immunity," <i>Immunology and Cell Biology</i> , 1995, 73, 389-396 | |
| | 16 | Lin, et al., "Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases," <i>Clinical Infectious Diseases</i> , December 1995, 21, 1439-1449 | |
| | 17 | Lofthouse, S.A., et al., "Parameters related to the application of recombinant ovine interleukin-1 β as an adjuvant," <i>Vaccine</i> , 1995, 13(14), 1277-1287 | |
| | 18 | MacDonald, H., et al., "Point mutations of human interleukin-1 with decreased receptor binding affinity," <i>FEBS Letters</i> , December 1986, 209(2), 295-298 | |
| | 19 | McMahan, C.J., et al., "A novel IL-1 receptor cloned from B cells by mammalian expression, is expressed in many cell types," <i>EMBO J</i> , 10(10), 2821-2832 | |
| | 20 | Mosley, B., et al., "Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 α and 1 β ," <i>Proc. Natl. Acad. Sci.</i> , July 1987, 84, 4572-4576 | |
| EXAMINER | | DATE CONSIDERED | |



| | | | |
|---|----|---|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0276/PA562.div | Application No. 10/684,774 |
| | | Applicant Richard S. Dondero, et al. | |
| | | Filing Date October 14, 2003 | Group Not Yet Assigned |
| | | Confirmation No. Not Yet Assigned | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 21 | Nakai, S. et al., "A Mutant Protein of Human Interleukin-1 β with Immunostimulatory But Not Pyrogenic Potency", <i>Life Sciences</i> , 1990 , <i>47</i> , 1707-1714 | |
| | 22 | Nash, A.D., et al., "Recombinant cytokines as immunological adjuvants," <i>Immunology and Cell Biology</i> , 1993 , <i>71</i> , 367-379 | |
| | 23 | Priestle, J.P., et al., "The three-dimensional structure of human interleukin-1 β refined to 2.0 A resolution," in <i>Cytokines and Lipocortins in Inflammation and Differentiation</i> , 1990 , 297-307 | |
| | 24 | Priestle, J.P., et al., "Crystal structure of the cytokine interleukin-1 β ," <i>The EMBO Journal</i> , 1988 , <i>7</i> (2), 339-343 | |
| | 25 | Seckinger, P., et al., "A urine inhibitor of interleukin 1 activity affects both interleukin 1 α and 1 β but not tumor necrosis factor α ," <i>J. Immunol.</i> , September 1, 1987 , <i>139</i> (5) | |
| | 26 | Sims, J.E., et al., "CDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily," <i>Science</i> , July 29, 1988 , <i>241</i> , 585-588 | |
| | 27 | Spriggs, M.K., et al., "Induction of an interleukin-1 receptor (IL-1R) on monocytic," <i>J. Biol. Chem.</i> , December 1990 , <i>265</i> (36), 22499-22505 | |
| | 28 | Staats and Ennis, "IL-1 Is an Effective Adjuvant for Mucosal and Systemic Immune Responses When Coadministered with Protein Immunogens", <i>The Journal of Immunology</i> , May 15, 1999 , <i>162</i> , 6141-6147 | |
| | 29 | Staats, H. F. et al., "IL-1 β Is an Effective Adjuvant for Nasal Vaccines", <i>Cytokine</i> , November, 1999 , <i>11</i> , 199 | |
| | 30 | Wu, H.-Y., et al., "Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity," <i>Vaccine</i> , 1994 , <i>12</i> , 215 | |
| EXAMINER | | DATE CONSIDERED | |



| | | | |
|---|----|--|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0276/PA562.div | Application No. 10/684,774 |
| | | Applicant Richard S. Dondero, et al. | |
| | | Filing Date October 14, 2003 | Group Not Yet Assigned |
| | | Confirmation No. Not Yet Assigned | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 31 | Young, P., et al., "A site-specific mutant of IL-1 β with reduced activity but wild-type binding," <i>Lymphokine Res.</i> , 1990, 9, 599 (Abstract No. 3.55) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| EXAMINER | | DATE CONSIDERED | |



| | | |
|---|---|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | Docket No. CELL-0276/ PA562.div | Application No. 10/684,774 |
| | Applicant Richard S. Dondero, et al. | |
| | Filing Date October 14, 2003 | Group Not Yet Assigned |
| | Confirmation No. Not Yet Assigned | |

U. S. PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Name | Class | Subclass |
|------------------|----|--------------|----------|------------------|-------|----------|
| | 32 | 5,206,014 | 04/27/93 | Nencioni, et al. | | |
| | 33 | 5,286,847 | 02/15/94 | Gehrke et al. | 530 | 351 |
| | 34 | 5,334,379 | 08/02/94 | Pillai, et al. | | |
| | 35 | 5,503,841 | 04/02/96 | Doyle, et al. | | |
| | 36 | 5,847,098 | 12/08/98 | Nakai et al. | 536 | 23.5 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Country | Translation | |
|------------------|----|--------------|----------|---------|-------------|----|
| | | | | | YES | NO |
| | 37 | WO 91/01143 | 07/16/90 | PCT | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|